anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The reliability and validity of the scale will begin with language equivalence and cultural adaptation. The scale will be translated from English to Turkish by two people who are fluent in Turkish and English. A single Turkish translation will be obtained from these two Turkish translations with a common opinion. The scale, which has been translated into Turkish, will be translated into English by two other people who are fluent in Turkish and English. The scale translated into English will be compared with the original. If the developer of the scale, miguel blacutt and Stults-Kolehmainen approves the translation of the scale, participants will be recruited for the study. In the pre-trial phase, a pre-assessment will be conducted with 15 participants to test the intelligibility of the scale. Based on the results of the pre-test phase, the final version of CRAVE will be able to be modified. RAVE scale questions and questions in the data collection form will be prepared through the google surveys and will be sent to the participants via Whatsapp, Facebook, Instagram and e-mail. Participants will fill out the survey forms online. 130 participants will be included in the study. In order to evaluate the validity of the CRAVE, the Behavioral Regulation in Exercise Questionnaire-2 (BREQ-2), which can measure exercise behaviors and intrinsic motivation and has been validated in Turkish, will be used. Scales will be repeated after 15 days to assess test-retest reliability.
The invention relates to a traditional Chinese medicine for treating encephalatrophy. The component proportion of the medicament is as follows: dahurian angelica root 10g, root of large-flowered skullcap 10g, cimicifuga foetida 10g, xanthium 10g, lily magnolia 10g, rhizoma Gastrodiae 10g, curcuma tuber 10g, sweetflag 10g, processed rhizoma arisaematis 10g, balloon flower root 10g and black tea 10g. The accuracy of the ratio of the fixed dosages is plus or minus 10% of the above components. The traditional Chinese medicine in the invention has the advantages of nourishing liver and kidney, replenishing vital essence and nourishing brain. Indications of the traditional Chinese medicine is encephalatrophy with the symptoms of forgetfulness, dizziness, palpitaition, insomnia, burnout and hypodynamia due to asthenia of both qi and blood. The traditional Chinese medicine has a safe and obvious effect on treating encephalatrophy and is free of any toxic or side effect.
Long depot follicular GnRH agonist protocol. On day 21 initiation of ovarian stimulation with recombinant FSH for ICSI. If necessary downregulation will be achieved with additional daily agonist s.c.
1,261,433. Treatment of hair. NATIONAL PATENT DEVELOPMENT CORP. 21 May, 1969 [10 July, 1968], No. 25949/69. Heading A5B. [Also in Division C3]  A process for treating hair on a human head comprises applying to the hair a cosmetic preparation which contains a hydrophilic polymer or copolymer of a hydroxy alkyl (C 2  to C 3 ) or hydroxy alkoxy (C 2  to C 3 ) alkyl (C 2  to C 3 ) acrylate or methacrylate. The preparations may be in the form of solutions (e.g. in alcohol), gels, pastes, creams or aerosol sprays and may include additives such as perfumes or essences, polyhydric alcohol plasticisers, silicone oil, polysucrose acrylate, polyoxyethylenenonyl phenol condensate and acetylated polyethoxylated lanolin. Treatments which can be effected include straightening kinky hair, setting or waving hair, imparting sheen to hair, and cleansing hair.
Mothers and their babies that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive Standard of care treatment. SOC treatment includes social work consult with information about follow up options for PPD.
Participants will be required to participate in an ESM data collection procedure. Participants will be required to complete a beep-questionnaire 3 days a week, over a 6-week period. The mobile app will be programmed to emit a beep 10 times per day at random intervals between 7.30 and 22.30. At each beep, participants will use the app to digitally complete a brief beep-questionnaire, which covers current affect, current context and activities. Moreover, participants will receive weekly standardized feedback on personalized patterns of positive affect.
The invention relates to a preparation method of a gene delivery system based on protein and platelet membrane modification, which specifically comprises the following steps: 1) Preparing a nano platelet membrane solution: 2) Preparation of Gene complexes: 3) Sample 4 was added dropwise to the gene complex at a ratio of 1-8. Mu.l: 10. Mu.g of sample 4 and BSA-PEI to obtain a gene delivery system based on protein and platelet membrane modification. The gene delivery system based on protein and platelet membrane modification prepared by the above preparation method. Use of a gene delivery system based on protein and platelet membrane modification for the preparation of a gene delivered drug. The invention has the advantages that: the biocompatibility and the gene loading capacity of the material are remarkably improved, the cytotoxicity is greatly reduced, the surface of a gene complex is coated with a platelet membrane which is used as a gene delivery system, the immune evasion capacity, the in-vivo stability and the gene delivery efficiency of the gene complex are improved, the migration and proliferation capacity of endothelial cells are greatly improved, and the purpose of better treating diseases is achieved.
Aged individuals with spinal cord injury (SCI) are prevalent with increased mortality and worse outcomes. SCI can cause secondary brain neuroinflammation and neurodegeneration. However, the mechanisms contributing to SCI-induced brain dysfunction are poorly understood. Cell-to-cell signaling through extracellular vesicles (EVs) has emerged as a critical mediator of neuroinflammation, including at a distance through circulation. We have previously shown that SCI in young adult (YA) male mice leads to robust changes in plasma EV count and microRNAs (miRs) content. Here, our goal was to investigate the impact of old age on EVs and brain after SCI. At 24 h post-injury, there was no difference in particle count or size distribution between YA and aged mice. However, aged animals increased expression of EV marker CD63 with SCI. Using the Fireplex® miRs assay, Proteomics, and mass spectrometry-based Lipidomics, circulating EVs analysis identified distinct profiles of miRs, proteins, and lipid components in old and injury animals. In vitro, plasma EVs from aged SCI mice, at a lower concentration comparable to those of YA SCI mice, induced the secretion of pro-inflammatory cytokines and neuronal apoptosis. Systemic administration of plasma EVs from SCI animals was sufficient to impair general physical function and neurological function in intact animals, which is associated with pro-inflammatory changes in the brain. Furthermore, plasma EVs from young animals had rejuvenating effects on naïve aged mice. Collectively, these studies identify the critical changes in circulating EVs cargoes after SCI and in aged animals and support a potential EV-mediated mechanism for SCI-induced brain changes.
The present invention is related to a method for preparing low molecular weight hyaluronic acid from high molecular weight hyaluronic acid which is produced by  Streptococcus  sp. ID9102 (KCTC11395BP). More specifically, the invention is related to a method of reducing the molecular weight of hyaluronic acid uniformly by reacting high molecular weight hyaluronic acid with an activated carbon in certain decomposition condition while maintaining original propertied of its own. The method of the invention for lowering a molecular weight of high molecular hyaluronic acid has a convenient process without the inconvenience of reprocessing for the removal of input materials, or requiring pH treatment, various reaction catalysts, and complicated additional treatment conditions (such as heat treatment) as in a conventional method. Furthermore, the method has an effect for removing impurities. Thus, through the method, it is possible to conveniently and economically produce low molecular weight hyaluronic acid with high purity. The inventive method for lowering the molecular weight has an advantage in that according to a change of a reaction condition using activated carbon, the molecular weight of low molecular weight hyaluronic acid can be variously adjusted. The low molecular weight hyaluronic acid produced by the method of the invention can be produced in accordance with the standards of medical supplies while the hyaluronic acid's own characteristic can be maintained. Also, it can be produced in accordance with the standards of cosmetics or foods.
IDH1-mutated gliomas are slow-growing brain tumors which progress into high-grade gliomas. The early molecular events causing this progression are ill-defined. Previous studies revealed that 20% of these tumors already have transformation foci. These foci offer opportunities to better understand malignant progression. The investigators used immunohistochemistry and high throughput RNA profiling to characterize foci cells. These have higher p-STAT3 staining revealing activation of JAK/STAT signaling. They downregulate genes involved in Hippo/Yap pathway (AMOT, CCDC80, LIX1), Wnt signaling (CPE, DAAM2, GPR37, SFRP2), EGFR signaling (EPS15, MLC1), cytoskeleton and cell-cell communication (EZR, GJA1) while increasing SKA3, a kinetochore-associated protein. In addition, foci cells show reduced levels of the lipid metabolic ethanolamine-phosphate phospho-lyase (ETNPPL/AGXT2L1). This enzyme is involved in the catabolism of phosphoethanolamine involved in membrane synthesis. The investigators detected ETNPPL protein in glioma cells as well as in astrocytes in the human brain. Its nuclear localization suggests additional roles for this enzyme. ETNPPL expression is inversely correlated to glioma grade and the investigators found no ETNPPL protein in glioblastomas.

Overexpression of ETNPPL reduces the growth of glioma stem cells indicating that this enzyme opposes gliomagenesis. Collectively, these results suggest that a combined alteration in membrane lipid metabolism and STAT3 pathway promotes IDH1-mutated glioma malignant progression.

Tumors with foci of at least four millimeters in diameter, assessed by hematoxylin \& eosin stainings, were selected. Four drills (two in foci and two in the other part of the tumor ) were performed in the FFPE tumor blocks using a two millimetres punch from a Tissue Micro Array apparatus in RNAse-free conditions. After the punches, the adequate selection of tumor areas was checked by hematoxylin \& eosin stainings of sections. Total RNA was extracted using the Qiagen RNeasy FFPE kit, quantified with Nanodrop 1000 (Thermo Fisher) and the RNA integrity number (RIN) was determined using a Bioanalyzer 2100. The RIN was on average 2.5 but were still suitable for labelling and hybridization on DNA chips according to the Affymetrix technical department. After amplification and labelling with an Affymetrix WT Pico Kit, cDNA were hybridized on Human Gene 2.1 ST chips. Data were normalized with the Affymetrix Expression Console software (GC-RMA algorithm) and the RNA profiles were generated using the Affymetrix Transcriptome Analysis Console (3.1.0.5) software. Differentially expressed genes were selected on the basis of a linear fold change ≥ 1.1 and p-value ≤ 0.05 (n=8 tumors). The data that support the findings of our study are openly available at the functional genomics data Gene Expression Omnibus.
PURPOSE:To obtain a deodorizing base material effective for mercaptan, etc. by forming acids such as inorg. and org. acids, inorg. alkalis or hydrolyzates of keratin materials such as protein decomposing enzymes in solvent solns. or adding the same to base materials for synthetic high polymer gels. CONSTITUTION:Hydrolyzates of keratin materials are contained. The hydrolyzates are formed by acid hydrolysis of keratin materials such as hair, feathers, nails, hoofs or the like by inorg. and org. acids or hydrolysis thereof by inorg. alkalis such as sodium hydroxide, potasium hydroxide or the like or hydrolysis by acidic protein decomposing enzymes such as pepsine, protease or the like, whereby the hydrolyzates of 200-5,000 average mol.wts. are obtained. Such hydrolyzates are dissolved in a solvent or are emulsified by using surfactants or are added to base materials for natural or synthetic high polymer gels such as agar-agar, carrageenan, polyethylene glycol or the like, whereby the compsn. for deodorizing and dehydrating agents is obtd.
OBJECTIVE: Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders, with diarrhea predominant IBS (IBS-D) as the most common subtype. Increasing evidence reported that the gut microbiota-mediated serotonin pathway plays a crucial role in the pathogenesis of IBS-D. In this study, potential herbal medicine, plant extracts and its monomers that can be employed as the candidate molecules for IBS-D through gut microbiota-mediated serotonin pathway were reviewed.
KEY FINDINGS: The bacteria indigenous to gut microbiota regulates serotonin pathway, mainly increasing tryptophan hydroxylase (TPH) and decreasing serotonin reuptake transporter (SERT), by activating cyclooxygenase/prostaglandin E2 (COX/PGE2) signaling. It further accelerated gastrointestinal motility and visceral hyperalgesia. Herbal medicine prescription including Tongxie yaofang and Shugan decoction, as well as some monomers of flavonoid and polyphenol compounds can be regarded as the potential agents for IBS-D. The predominate mechanisms were related to regulating serotonin pathway by driving on the specific bacterial abundance (such as Firmicutes and Bacteroidetes). However, there are few reports on which specific bacteria species play a regulatory role in serotonin pathway, and most of these effective agents were only evidenced by preclinical studies. We hope this review will provide some useful directions for the treatment strategy of IBS-D.
Acetaminophen and codeine phosphate tablets contain codeine. Codeine in combination with acetaminophen, is a Schedule III controlled substance. As an opioid, acetaminophen and codeine phosphate tablets expose users to the risks of addiction, abuse, and misuse (see DRUG ABUSE AND DEPENDENCE). 

Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed acetaminophen and codeine phosphate tablets. Addiction can occur at recommended dosages and if the drug is misused or abused. 

Assess each patient’s risk for opioid addiction, abuse, or misuse prior to prescribing acetaminophen and codeine phosphate tablets, and monitor all patients receiving acetaminophen and codeine phosphate tablets for the development of these behaviors and conditions. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). The potential for these risks should not, however, prevent the proper management of pain in any given patient. Patients at increased risk may be prescribed opioids such as acetaminophen and codeine phosphate tablets, but use in such patients necessitates intensive counseling about the risks and proper use of acetaminophen and codeine phosphate tablets along with intensive monitoring for signs of addiction, abuse, and misuse. Consider prescribing naloxone for the emergency treatment of opioid overdose (see WARNINGS, Life-Threatening Respiratory Depression; DOSAGE AND ADMINISTRATION, Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose).

Opioids are sought by drug abusers and people with addiction disorders and are subject to criminal diversion. Consider these risks when prescribing or dispensing acetaminophen and codeine phosphate tablets. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity and advising the patient on the proper disposal of unused drug (see PRECAUTIONS; Information for Patients/Caregivers). Contact local state professional licensing board or state controlled substances authority for information on how to prevent and detect abuse or diversion of this product.
OBJECTIVE: Pregnant and postpartum women (PPW) in Southern Africa are at increased risk of acquiring HIV and curable sexually transmitted infections (STIs). Oral pre-exposure prophylaxis (PrEP) is safe and effective to use during pregnancy to reduce HIV acquisition and vertical transmission. Point-of-care (POC) STI testing can identify PPW at risk of HIV and facilitate risk-differentiated and person-centred counselling to improve PrEP initiation, persistence and adherence. We evaluated the impact of POC STI testing compared with STI syndromic management on PrEP outcomes among PPW in Cape Town, South Africa.
METHODS: The STI and PrEP in Pregnancy Study enrolled PPW without HIV and ≤34 weeks pregnant at their regular antenatal care visit with follow-up after 1 month. PPW were randomised to receive POC STI testing or STI syndromic management. PPW randomised to POC STI testing self-collected vaginal swabs for Chlamydia trachomatis, Neisseria gonorhoeae and Trichomonas vaginalis (Cepheid GeneXpert) testing and were offered same-day treatment if diagnosed. We compared PrEP initiation at baseline, PrEP prescription refill at 1 month (persistence) and adherence through tenofovir-diphosphate detection in dried blood spots by randomisation arm. In a secondary analysis, we evaluated the association between an STI diagnosis (positive STI test or reporting STI symptoms) with PrEP outcomes.
RESULTS: We enrolled and randomised 268 pregnant women. Twenty-eight per cent of women were diagnosed with ≥1 STI. Overall, 65% of women initiated and 79% persisted on PrEP with no significant differences by randomisation arm. Secondary analysis demonstrated that an STI diagnosis (positive STI test or reporting STI symptoms) was associated with higher PrEP initiation (adjusted relative risk=1.28; 95% CI 1.08 to 1.52), controlling for arm, maternal and gestational age.
CONCLUSIONS: POC STI testing was not associated with PrEP initiation or persistence relative to syndromic management. However, improving STI diagnosis by supplementing syndromic management with POC STI testing could improve PrEP initiation among PPW.
TRIAL REGISTRATION NUMBER: NCT03902418; Clinical Trials.gov; 1 April 2019.
The TIAP study aims to study the transferability of a local innovation in the field of inclusive education in order to identify the functions that can be transferred. Grounded in a theory based evaluation (called realist evaluation) the TIAP study is a qualitative case study. The study population comprises various participant profiles including students with disabilities, students without disabilities, families, educational professionals, social workers and professionals/volunteers working in recreational activities. Participants will be recruited in two schools from a French department (Eure et Loir). In this department the intervention (also called innovation) is implemented. This intervention implies a complete transformation carried out by the service providers for students with intellectual deficiencies as well as the educational system. Students with disabilities go at school in their geographical area. They attend a standard classroom and have educational and therapeutical support offered by the local service provider (DAME : Dispositif d'Accompagnement Médico-Educatif ). Service providers are seen as ressources for education professionals.

Qualitative data will be collected by interviewers through individual or collective interviews, Data collection will be based on the configurational elements Contest, Mechanisms, Outcomes based on a realist evaluation.
Thermoregulation is impaired in individuals with a spinal cord lesion (SCI), affecting sweat capacity, heat loss, and core temperature. This can be particularly problematic for athletes with SCI who exercise in hot and humid conditions, like those during the Tokyo 2020 Paralympic Games. Heat acclimation can support optimal preparation for exercise in such challenging environments, but evidence is limited in endurance athletes with SCI. We evaluated whether seven consecutive days of exercise in the heat would result in heat acclimation. Five elite para-cycling athletes with SCI participated (two females, three males, median (Q1-Q3) 35 (31-51) years, four with paraplegia and one with tetraplegia). All tests and training sessions were performed in a heat chamber (30°C and 75% relative humidity). A time-to-exhaustion test was performed on day 1 (pretest) and day 7 (posttest). On days 2-6, athletes trained daily for one hour at 50-60% of individual peak power (PPeak). Comparing pretest and posttest, all athletes increased their body mass loss (p=0.04), sweat rate (p=0.04), and time to exhaustion (p=0.04). Effects varied between athletes for core temperature and heart rate. All athletes appeared to benefit from our heat acclimation protocol, helping to optimize their preparation for the Tokyo 2020 Paralympic Games.
A prospective observational study in inpatient care within community-based management of acute malnutrition(CMAM) program run by the nongovernmental organization called Alliance for International Medical Action (ALIMA) within the University of Maiduguri Teaching Hospital, Maiduguri, Nigeria

The objectives of the study are to validate the BedsidePEWS scores as a measure of severity of illness in children who are treated as inpatients for severe acute malnutrition and to compare the BedsidePEWS scores with other risk factors associated for mortality and relapse of children with severe acute malnutrition. The design is a prospective observational study of 1000 children admitted as inpatients in a CMAM program in Maidaguri Teaching Hospital in Maidaguri, Nigeria. Data collection (estimated duration 4-5 months) involves vital signs, and risk factor assessment every 12 hours for duration of hospitalization. Blood test for hemoglobin and malaria will be done once upon admission. Outcomes will be measured every 12 hours and include mortality and/or escalation and de-escalation of care. Logistic regression with significance testing will be used to compare BedsidePEWS scores and risk factors between patients and among individual patients within the outcome categories. Exploratory sensitivity analyses will repeat the main logistic regression analyses to evaluate the performance of partial BedsidePEWS score in patients with missing data of 1-3 of the 7 components, by randomly removing 1-3 data elements from the score calculation from patients, and by removing systolic blood pressure from scoring.
Participants receive MK-3475A (pembrolizumab Conc2 \[dose 1\] + MK-5180) SC on Day 1 of Cycles 1 and 3 plus 400 mg pembrolizumab IV on Day 1 of Cycles 2 and 4 to 18, with or without background SOC chemotherapy as appropriate for the indication. A cycle is 42 days.
Nicardipine was embryocidal when administered orally to pregnant Japanese White rabbits, during organogenesis, at 150 mg/kg/day (a dose associated with marked body weight gain suppression in the treated doe) but not at 50 mg/kg/day (25 times the maximum recommended antianginal or antihypertensive dose in man). No adverse effects on the fetus were observed when New Zealand albino rabbits were treated, during organogenesis, with up to 100 mg nicardipine/kg/day (a dose associated with significant mortality in the treated doe). In pregnant rats administered nicardipine orally at up to 100 mg/kg/day (50 times the maximum recommended human dose) there was no evidence of embryolethality or teratogenicity. However, dystocia, reduced birth weights, reduced neonatal survival, and reduced neonatal weight gain were noted. There are no adequate and well‑controlled studies in pregnant women. Nicardipine hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.